NCT04379401View on ClinicalTrials.gov

Acute Impact of Cardiac Resynchronization on Vascular Function (RVA-CRT)

NACompletedINTERVENTIONAL
Enrollment

35

Participants

Timeline

Start Date

January 1, 2021

Primary Completion Date

June 20, 2023

Study Completion Date

June 20, 2023

Conditions
Heart Failure
Interventions
DEVICE

Cardiac Resynchronization Therapy (ON vs. OFF)

This study involves study participants, who already received cardiac resynchronisation therapy implantation for clinical reasons. CRT is authorized for medical use by Swissmedic in Switzerland and all implanted devices are CE-approved.

Trial Locations (1)

8091

UniversitätsSpital Zürich, Zurich

All Listed Sponsors
lead

Andreas Flammer

OTHER

NCT04379401 - Acute Impact of Cardiac Resynchronization on Vascular Function (RVA-CRT) | Biotech Hunter | Biotech Hunter